Brussels, 09/10/2012 (Agence Europe) - On Friday 5 October, the European Commission cleared the EU proposed acquisition of the Swiss-based pharmaceutical company Actavis by the generic pharmaceutical company Watson of the United States.
The Commission examined the effects of the proposed transaction on the markets for a number of drugs, such as anti-depressants and anti-hypertensives, in particular in Denmark, Sweden and the UK. The investigation showed that despite significant changes in the competitive situation in some of the markets, a sufficient number of credible and strong competitors will continue to exercise a competitive constraint on the merged entity.
The Commission therefore concluded that the proposed transaction would not significantly impede effective competition in the European Economic Area or a substantial part of it. (OL/trans.fl)